Breaking News Instant updates and real-time market news.

ONTX

Onconova

$0.11

-0.0264 (-18.86%)

17:28
11/26/19
11/26
17:28
11/26/19
17:28

Point72 Asset Management reports 9.99% passive stake in Onconova

Point72 Asset Management disclosed a 9.99% stake in Onconova, which represents over 3.23M shares. The filing does not allow for activism.

ONTX Onconova
$0.11

-0.0264 (-18.86%)

12/03/18
12/03/18
NO CHANGE

Onconova presents rigosertib with azacitidine data at ASH
Onconova Therapeutics announced the presentation of the efficacy and safety results of oral rigosertib in combination with azacitidine in patients with HR-MDS reported at an oral presentation during the American Society of Hematology, or ASH. Rigosertib, the company's lead compound, is being evaluated in both intravenous and oral forms. Seventy-four patients were treated with a median age of 69 years at nine clinical sites and received either 840 mg or 1,120 mg of oral rigosertib daily divided into two doses, in combination with a standard dose of injectable azacitidine. Of the 55 evaluable patients, 29 patients were treated with a daily dose of 1,120 mg of oral rigosertib, either 560 mg twice daily or 840 mg in the a.m. and 280 mg in the afternoon. Twenty-six patients were treated with 560 mg in the AM and 280 mg in the PM for the first three weeks of a four-week cycle. All patients also received 75 mg/m2/day SC or IV azacitidine during the second week of the four-week cycle. The median duration of treatment for the HMA naive and HMA failed patients was 7.8 and 4.9 months respectively. The median duration of response in these groups was 12.2 and 10.8 months, respectively. The overall response rate, or ORR, using the IWG 2006 criteria, in 29 HMA naive patients was 90%, including 10 patients with complete remission, or CR. Among the 26 evaluable HMA-failed patients the ORR was 54% including 8% CR or PR. The median time to initial and best response were 1 and 4 cycles in the HMA naive group and 2 and 5 cycles in the HMA failed group. The safety population received at least 1 dose of oral rigosertib. The combination was well tolerated. Other than genitourinary adverse events, or AEs, the AE profile was similar to those described for azacitidine alone in this patient population. Genitourinary AEs, including hematuria and dysuria were observed. A safety optimization strategy was implemented for the higher dose cohort of 1,120 mg of oral rigosertib. These strategies included earlier in the day administration of the PM dose, oral hydration, monitoring of urinary pH and mandatory bladder emptying at night. Collectively these strategies resulted in mitigation of the target genitourinary AEs, including reduction of genitourinary grade 3 AEs reported from an earlier cohort despite receiving a higher dose of oral rigosertib. In conclusion, oral rigosertib in combination with azacitidine was well tolerated in HMA naive and HMA failed HR-MDS patients. The combination produced an encouraging rate of overall response and complete remission in both groups. The safety optimization strategies and increased dose exploration of oral rigosertib in the combination is leading to the development of a pivotal Phase 3 trial in HMA and chemotherapy naive patients. Onconova plans to meet with the FDA to discuss the results of the Phase 2 trial and the planned Phase 3 trial, and to seek a special protocol assessment. The company has partnered rigosertib with SymBio Pharmaceuticals, for Japan and Korea, and with Pint Pharma for Latin American countries. Both partners have indicated their interest in participating in the proposed new pivotal Phase 3 trial by enrolling patients in their respective territories. SymBio is currently conducting Phase 1 studies with oral rigosertib in Japan and also participating in the Phase 3 global INSPIRE trial. The company is also actively seeking additional collaborations for rigosertib in other geographies.
07/25/19
NBLE
07/25/19
INITIATION
Target $12
NBLE
Outperform
Onconova initiated with an Outperform at Noble Capital
Noble Capital analyst Ahu Demir initiated Onconova with an Outperform rating and $12 price target, noting that the company's Phase 3 INSPIRE study of rigosertib in patients with high-risk myelodysplastic syndrome is expected to have a data readout in 2020. While the company's main focus is MDS, Demir sees it having promising early stage opportunities beyond MDS, he noted. He believes the current stock price does not reflect the potential of Onconova's pipeline, Demir added.
07/25/19
07/25/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. FleetCor (FLT) initiated with a Neutral at Baird. 2. Medifast (MED) initiated with a Buy at Jefferies. 3. EnLink Midstream (ENLC) initiated with a Neutral at Mizuho. 4. Onconova (ONTX) initiated with an Outperform at Noble Capital. 5. Gold Standard Ventures (GSV) initiated with a Buy at B. Riley FBR. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/26/19
MAXM
11/26/19
DOWNGRADE
MAXM
Hold
Onconova downgraded to Hold from Buy at Maxim
Maxim analyst Jason McCarthy downgraded Onconova to Hold from Buy.

TODAY'S FREE FLY STORIES

XP

XP

$0.00

(0.00%)

11:41
12/11/19
12/11
11:41
12/11/19
11:41
Syndicate
Breaking Syndicate news story on XP »

XP opens at $32.75, IPO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

LEN

Lennar

$59.55

0.425 (0.72%)

11:35
12/11/19
12/11
11:35
12/11/19
11:35
Options
Lennar put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBSI

Barrett Business

$89.46

0.01 (0.01%)

11:33
12/11/19
12/11
11:33
12/11/19
11:33
Conference/Events
Barrett Business management to meet with Barrington »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 13

    Dec

CHSCP

CHS Inc.

$28.30

0.09 (0.32%)

11:33
12/11/19
12/11
11:33
12/11/19
11:33
Hot Stocks
CHS obtains exclusive rights to Corteva Agriscience sunflower breeding program »

CHS announced that it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRXC

TransEnterix

$0.17

-0.0057 (-3.19%)

11:31
12/11/19
12/11
11:31
12/11/19
11:31
Hot Stocks
TransEnterix announces one-for-thirteen reverse stock split »

TransEnterix announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

TM

Toyota

$141.55

0.38 (0.27%)

11:31
12/11/19
12/11
11:31
12/11/19
11:31
Hot Stocks
Toyota announces executive leadership changes in North America »

Toyota Motor North…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XP

XP

$0.00

(0.00%)

11:29
12/11/19
12/11
11:29
12/11/19
11:29
Syndicate
Breaking Syndicate news story on XP »

XP indicated to open at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

11:29
12/11/19
12/11
11:29
12/11/19
11:29
Conference/Events
JPMorgan U.S. Internet analyst to hold an analyst/industry conference call »

U.S. Internet Analyst…

11:26
12/11/19
12/11
11:26
12/11/19
11:26
Conference/Events
JPMorgan airfreight/surface transport to hold analyst/industry conference call »

Airfreight & Surface…

WORK

Slack Technologies

$20.90

-1.36 (-6.11%)

11:25
12/11/19
12/11
11:25
12/11/19
11:25
Options
Slack call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:25
12/11/19
12/11
11:25
12/11/19
11:25
General news
The U.S. QSS figures that track activity for the service sector »

The U.S. QSS figures that…

ALNA

Allena Pharmaceuticals

$1.96

-0.04 (-2.00%)

11:25
12/11/19
12/11
11:25
12/11/19
11:25
Conference/Events
Roth Capital healthcare analyst to hold an analyst/industry conference call »

Healthcare Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

NFLX

Netflix

$298.07

4.86 (1.66%)

, DIS

Disney

$147.33

1.21 (0.83%)

11:22
12/11/19
12/11
11:22
12/11/19
11:22
Periodicals
Netflix tests discounts for purchase of full year of service, BGR reports »

Netflix (NFLX) is testing…

NFLX

Netflix

$298.07

4.86 (1.66%)

DIS

Disney

$147.33

1.21 (0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
12/11/19
12/11
11:17
12/11/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
12/11/19
12/11
11:16
12/11/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DISH

Dish

$34.06

0.51 (1.52%)

11:15
12/11/19
12/11
11:15
12/11/19
11:15
Options
Dish put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALNA

Allena Pharmaceuticals

$1.96

-0.04 (-2.00%)

11:15
12/11/19
12/11
11:15
12/11/19
11:15
Conference/Events
Roth Capital biotech analyst to hold an analyst/industry conference call »

Biotechnology Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

ALGT

Allegiant Travel

$172.80

0.57 (0.33%)

11:06
12/11/19
12/11
11:06
12/11/19
11:06
Hot Stocks
Allegiant Travel reports November scheduled service RPMs up 1.6% »

Allegiant Travel reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HII

Huntington Ingalls

$251.05

-0.74 (-0.29%)

11:05
12/11/19
12/11
11:05
12/11/19
11:05
Hot Stocks
Huntington Ingalls appoints Bharat Amin as EVP, CIO »

Huntington Ingalls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CIEN

Ciena

$35.35

0.65 (1.87%)

11:05
12/11/19
12/11
11:05
12/11/19
11:05
Options
Ciena call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

AMZN

Amazon.com

$1,738.75

-0.4 (-0.02%)

11:01
12/11/19
12/11
11:01
12/11/19
11:01
Periodicals
Alexa devices sell out in parts of Europe before Christmas, Bloomberg reports »

Amazon's new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVER

EverQuote

$34.09

-1.95 (-5.41%)

11:01
12/11/19
12/11
11:01
12/11/19
11:01
On The Fly
EverQuote down after Bonitas says it expects stock to drop to about $5 »

Shares of EverQuote…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:01
12/11/19
12/11
11:01
12/11/19
11:01
Conference/Events
JPMorgan banking analyst to hold an analyst/industry conference call »

U.S. Mid & Small Cap…

LOGM

LogMeln

$74.20

0.24 (0.32%)

10:59
12/11/19
12/11
10:59
12/11/19
10:59
Hot Stocks
Breaking Hot Stocks news story on LogMeln 

LogMein trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOGM

LogMeln

$74.20

0.24 (0.32%)

10:58
12/11/19
12/11
10:58
12/11/19
10:58
Hot Stocks
LogMeln up 6% after report of private equity takeover talks »

Shares of LogMeIn are up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.